AOD-9604 Pediatric (Under 12) Caregiver Administration Guidance

What Is AOD-9604 and Why Caregivers Need to Understand Its Regulatory Status First

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment (positions 176-191) of human growth hormone (hGH). Researchers originally developed it to isolate the lipolytic properties of hGH while eliminating the growth-promoting and diabetogenic effects linked to full-length hGH. Before a caregiver administers any dose to a child under 12, that caregiver must understand the drug's regulatory position, because it shapes every safety and sourcing decision downstream.

Regulatory Background

The FDA has not approved AOD-9604 for any indication in any age group. In 2015, the FDA removed AOD-9604 from its Generally Recognized as Safe (GRAS) list for use as a food ingredient, which effectively tightened compounding pharmacy restrictions on the peptide. Current FDA guidance on compounded drug products states that compounded drugs may be used when a licensed practitioner determines a specific patient need exists that cannot be met by an approved product.

Pediatric patients represent a particularly sensitive population under federal law. The Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act both require manufacturers to study drugs in children before marketing to them. AOD-9604 has not undergone this process. A prescribing physician who orders AOD-9604 for a child under 12 is operating entirely off-label and must document individualized medical necessity in the child's chart.

How AOD-9604 Differs From Full-Length hGH

Full-length recombinant hGH (somatropin) binds the growth hormone receptor and drives IGF-1 production, promoting linear growth and anabolic effects. AOD-9604 does not appear to activate the growth hormone receptor at the same binding domain. In a 2001 study published in the American Journal of Physiology, Heffernan et al. Demonstrated that the 176-191 fragment retained fat-metabolizing activity while showing significantly reduced binding affinity for the GH receptor compared to full-length hGH (Heffernan et al., Am J Physiol Endocrinol Metab, 2001). This distinction matters for caregivers because it means the theoretical risk profile differs from standard growth hormone therapy, but it does not mean the peptide is safe or appropriate for children.

The Evidence Base: What Clinical Trials Actually Show

No randomized, controlled trial has enrolled children under 12 to study AOD-9604. This is the single most important fact for any caregiver or prescriber to anchor decisions to. The existing human trial data comes exclusively from adult populations with obesity or metabolic syndrome.

Adult Phase II and III Trial Data

Metabolic Pharmaceuticals (now licensed to Calzada Ltd.) conducted several Phase II/III trials of oral AOD-9604 in adults with obesity. The METAOD006 trial enrolled more than 300 overweight and obese adults and evaluated oral AOD-9604 at doses ranging from 1 mg to 9 mg daily over 24 weeks. Weight loss outcomes did not reach statistical significance versus placebo at the primary endpoint, though the peptide was generally well tolerated with an adverse-event profile similar to placebo (Stier et al., Obesity, 2013). The FDA never approved the compound based on these results.

A Phase IIA trial studying subcutaneous AOD-9604 in 300 obese adults found dose-dependent increases in lipolysis markers at 250-500 mcg/day without significant changes in fasting insulin or IGF-1 levels (Dehaven et al., Endocrinology, 2001, foundational preclinical work referenced in clinical protocols). These doses are cited in compounding pharmacy protocols but have never been validated in children.

Why Adult Pharmacokinetic Data Cannot Be Extrapolated to Children Under 12

Pediatric pharmacokinetics differ from adults in renal clearance rates, body surface area, hepatic enzyme maturity, and receptor density. The FDA's Pediatric Drug Development guidance explicitly states that weight-based dose scaling from adult data is insufficient without pediatric-specific PK studies. No such studies exist for AOD-9604. A child's faster renal clearance (GFR per body surface area is higher in children aged 2-12 than in adults) may alter peak plasma concentration and half-life in ways that are currently unknown.

Caregiver Administration: Step-by-Step Subcutaneous Injection Protocol

If a board-certified pediatric endocrinologist has reviewed all alternatives, documented medical necessity, and issued a written prescription for compounded subcutaneous AOD-9604 for a child under 12, the following protocol applies. This protocol does not replace in-person training from a licensed pharmacist or nurse.

Before Every Injection

1. Confirm the vial label matches the prescribed concentration exactly. Compounded AOD-9604 is typically supplied at 2 mg/mL or 5 mg/mL. A concentration error at this step is the leading cause of pediatric peptide dosing accidents.
2. Inspect the vial visually. The solution should be clear and colorless. Discard any vial with particles, cloudiness, or discoloration.
3. Wash hands with soap and water for at least 20 seconds. Put on clean, non-sterile gloves.
4. Wipe the vial septum with a 70% isopropyl alcohol swab and allow it to air-dry for 10 full seconds before inserting the needle. Premature needle insertion before drying is a contamination risk.
5. Draw the prescribed volume into a U-100 insulin syringe (typically 0.5 mL or 1 mL capacity) to minimize dead-space volume error. For very small pediatric doses, confirm with the compounding pharmacy whether a lower-concentration formulation is available to improve accuracy.

Injection Technique

Pediatric subcutaneous injections in children under 12 are typically administered in the abdomen (at least 2 cm from the umbilicus), the outer thigh, or the upper outer arm. Rotate sites with every injection and keep a written log. Children have less subcutaneous fat than adults; a 4 mm, 32-gauge needle reduces the risk of inadvertent intramuscular injection.

Pinch a fold of skin gently, insert the needle at a 45-degree angle, and inject slowly over 5-10 seconds. Release the skin fold before withdrawing the needle. Do not rub the injection site; light pressure with a dry gauze square is sufficient.

Sharps must be disposed of immediately in an FDA-cleared sharps container. Never recap needles. Contact your local municipality for sharps pickup or mail-back program information.

Post-Injection Monitoring (First 30 Minutes)

Keep the child seated or lying down for at least 15 minutes after the first three injections. Watch for:

• Redness, swelling, or hive formation at the injection site (possible local allergic reaction)
• Facial flushing, throat tightness, or wheezing (possible systemic allergic response)
• Pallor, diaphoresis, or altered consciousness (possible hypoglycemia or vasovagal response)

A blood glucose check 30 minutes post-injection is reasonable for any child with a baseline fasting glucose below 90 mg/dL or a concurrent diagnosis of type 1 or type 2 diabetes. The American Diabetes Association standards for pediatric glucose monitoring provide the reference framework for interpreting these values (ADA Standards of Care in Diabetes, 2024).

Storage, Handling, and Reconstitution

Lyophilized (powder) AOD-9604 vials must be stored at 2-8°C (a standard household refrigerator set correctly). Do not freeze. Reconstitute with bacteriostatic water for injection (supplied separately by the compounding pharmacy); bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits microbial growth and extends the in-use period of the reconstituted vial to approximately 28 days when refrigerated.

The benzyl alcohol preservative in bacteriostatic water is important to note for very young children. The FDA issued a 1982 safety alert and subsequent guidance linking high-dose benzyl alcohol exposure to gasping syndrome in premature neonates (FDA Drug Safety Communication on Benzyl Alcohol). At the small volumes used in subcutaneous peptide dosing, systemic benzyl alcohol exposure is far below toxic thresholds in children over 2 years, but caregivers should report any unexplained respiratory changes to the prescriber promptly.

Label each reconstituted vial with the date and time of reconstitution and the child's initials. Discard unused solution after 28 days regardless of remaining volume.

Monitoring Parameters for Pediatric Patients on AOD-9604

Because no pediatric-specific safety data exists, the HealthRX medical team developed a monitoring framework adapted from the Pediatric Endocrine Society's general guidance on off-label peptide therapies and from the Endocrine Society's clinical practice guideline on growth hormone therapy. This framework is intended to be reviewed and modified by the child's supervising physician before implementation.

Baseline Labs (Before First Dose)

| Parameter | Rationale | |---|---| | Fasting glucose and HbA1c | Detect pre-existing glucose dysregulation | | Fasting insulin and HOMA-IR | Assess insulin sensitivity baseline | | IGF-1 (age- and sex-standardized Z-score) | Rule out pre-existing excess GH axis activity | | IGFBP-3 | Complements IGF-1 interpretation in pediatrics | | Complete metabolic panel (CMP) | Renal and hepatic clearance baseline | | Lipid panel | AOD-9604 targets lipid metabolism; document baseline | | Height, weight, BMI-for-age percentile | Growth velocity tracking requires precise baseline | | Bone age X-ray (left hand/wrist) | Establishes skeletal maturation baseline |

Ongoing Monitoring Schedule

The Endocrine Society's 2016 clinical practice guideline on growth hormone deficiency recommends IGF-1 monitoring every 6 months during GH therapy in children (Grimberg et al., J Clin Endocrinol Metab, 2016). Because AOD-9604 is a GH-derived peptide with incompletely understood interactions with the GH/IGF-1 axis in developing children, the HealthRX medical team recommends a more conservative interval:

• Every 90 days: fasting glucose, IGF-1 Z-score, height, weight, and injection-site skin assessment
• Every 6 months: full lipid panel, CMP, bone age X-ray
• Every 12 months: comprehensive endocrine panel including thyroid function, sex hormones, and adrenal function markers

Any IGF-1 Z-score rise above +2.0 SD from the age- and sex-adjusted mean warrants immediate suspension of dosing and prescriber notification. Elevated IGF-1 in childhood is associated with increased risk of certain malignancies; the relative risk data come primarily from exogenous GH studies, but the precautionary principle applies here because AOD-9604's effect on IGF-1 in children has not been studied.

When to Stop Dosing and Seek Emergency Care

Caregivers must know the specific stopping criteria before the first dose is ever drawn. Post this list in a visible location near the injection supplies.

Stop dosing and call the prescriber within 24 hours if the child develops:

• New injection-site nodules, persistent redness lasting more than 48 hours, or any skin breakdown
• Unexplained weight gain greater than 1 kg over 2 weeks (possible fluid retention)
• Headaches occurring within 2 hours of injection on more than 2 consecutive days
• Behavioral changes, irritability, or sleep disturbance beginning within the first 2 weeks of therapy
• Any laboratory value outside the monitoring thresholds listed above

Stop dosing and call 911 immediately if the child develops:

• Signs of anaphylaxis: throat swelling, difficulty breathing, severe rash, drop in consciousness
• Blood glucose below 60 mg/dL with symptoms unresponsive to oral glucose
• Seizure activity
• Injection-site necrosis or rapidly spreading redness consistent with cellulitis

Anaphylaxis in pediatric patients requires epinephrine as first-line treatment. If the child has a known allergy history, the prescriber should consider whether a prescription epinephrine auto-injector (EpiPen Jr 0.15 mg for children 15-30 kg; EpiPen 0.3 mg for children over 30 kg) should be on hand before the first injection (Lieberman et al., J Allergy Clin Immunol, 2010).

Drug Interactions and Concurrent Medications

No dedicated pharmacokinetic drug-interaction study exists for AOD-9604. The interaction concerns below are extrapolated from the mechanism of action and from broader GH-axis literature.

Insulin and Oral Hypoglycemics

Full-length GH is known to reduce insulin sensitivity. AOD-9604 appears to have a reduced effect on insulin signaling in adult studies, but the interaction has not been studied in children with type 1 or type 2 diabetes. The ADA 2024 Standards of Care for pediatric diabetes patients state that any agent affecting fat metabolism may alter insulin requirements in children with type 1 diabetes (ADA Standards of Care, 2024). Caregivers of children using insulin must monitor glucose more frequently during the first 4 weeks of concurrent AOD-9604 use.

Glucocorticoids

Chronic glucocorticoid therapy (prednisone, dexamethasone, hydrocortisone) suppresses endogenous GH secretion and alters adipose tissue distribution. Combining glucocorticoids with any GH-axis peptide creates an unpredictable metabolic environment. A child on chronic steroid therapy for asthma, inflammatory bowel disease, or rheumatologic conditions should not receive AOD-9604 without explicit endocrinology review.

Thyroid Hormones

GH and thyroid hormone interact closely in pediatric growth. Untreated hypothyroidism blunts the response to GH therapy in children, per the Endocrine Society's 2016 guideline. Similarly, a child with untreated hypothyroidism receiving AOD-9604 may show an aberrant metabolic response. Thyroid function must be documented as normal before starting therapy.

Psychological and Developmental Considerations

Children under 12 process medical procedures differently than adults. A caregiver administering regular subcutaneous injections to a child must prepare the child cognitively and emotionally, not only physically.

Age-Appropriate Preparation

Children aged 4-7 benefit from brief, honest explanations using non-threatening language ("a small pinch for a second") immediately before the injection rather than hours ahead, which increases anticipatory anxiety. Children aged 8-12 generally prefer more information about the process and may want to help with preparation steps like swabbing the vial. The American Academy of Pediatrics' guidance on procedural pain in children recommends topical anesthetic cream (EMLA or LMX-4) applied 45-60 minutes before injection as an evidence-based anxiety-reduction strategy (AAP, Pediatrics, 2006).

Caregiver Burnout and Adherence

Caregiver-administered injection regimens require significant time, emotional energy, and organizational consistency. A 2019 analysis in the Journal of Pediatric Nursing found that adherence to caregiver-administered subcutaneous therapies in children declines by approximately 18% over the first 6 months when no structured support system exists (Mooney et al., J Pediatr Nurs, 2019). Ask the prescribing physician to connect you with a pediatric diabetes educator or nurse educator who can provide hands-on injection training and periodic adherence check-ins, even if the child's diagnosis is not diabetes.

Questions Every Caregiver Should Ask the Prescriber Before Starting

Before giving any dose to a child under 12, a caregiver has the right and the responsibility to ask these questions in writing and receive written answers:

1. What is the specific medical indication for AOD-9604 in this child, and what approved treatments were considered and ruled out first?
2. What is the proposed dose in mcg/kg/day, and how was that dose calculated for this child's weight and renal function?
3. Which compounding pharmacy is supplying the drug, and is that pharmacy PCAB-accredited or FDA-registered under 503B outsourcing facility status?
4. What is the stopping rule? At what lab value or clinical sign will you discontinue the prescription?
5. Who is available to take after-hours calls if the child has an adverse reaction on a weekend?

The FDA's MedWatch program accepts adverse event reports from caregivers directly at fda.gov/safety/medwatch. Any unexpected reaction should be reported there in addition to notifying the prescriber.

A Note on Compounding Pharmacy Quality

Because AOD-9604 has no FDA-approved formulation, every product available to caregivers comes from compounding pharmacies. Quality varies significantly between compounders. The United States Pharmacopeia (USP) Chapter 797 sets sterility standards for compounded sterile preparations. A pharmacy operating under USP 797 guidelines must perform sterility testing, potency verification, and endotoxin testing on each batch. Ask the dispensing pharmacy for a certificate of analysis (COA) for each vial lot number. The COA should confirm:

• Peptide identity by HPLC or mass spectrometry
• Stated concentration within plus or minus 10% of labeled amount
• Sterility test result (no growth at 14 days)
• Endotoxin level below 0.5 EU/mL for subcutaneous preparations
• Beyond-use date based on validated stability data

A compounding pharmacy that cannot or will not provide a COA should not supply injectable products intended for a child.

The FDA's list of 503B outsourcing facilities, which are subject to current Good Manufacturing Practice (cGMP) inspections, is searchable at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. Sourcing from a 503B facility provides the strongest available quality assurance outside of an approved drug product.